By Fineline Cube 
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2) and six months (H1) ended June 30, 2025. The company achieved total revenue of USD 255.058 million in Q2, representing a 36.7% increase year-over-year. For H1, total revenue reached USD 450.111 million, a significant 60.4% increase year-over-year.
Revenue Breakdown
- License Revenue:
- Q2: USD 35.338 million
- H1: USD 44.686 million
- Collaboration Revenue:
- Q2: USD 219.717 million
- H1: USD 405.332 million
Revenue Sources
Legend Biotech’s license revenue primarily arises from licensing transactions with Novartis, related to LB2102 and other specific DLL-3-targeted CAR-T therapies. Collaboration revenue is mainly derived from income sharing based on Janssen’s sales of Carvykti (Ciltacabtagene Autoleucel). Notably, the license agreement with Janssen for the commercialization of Carvykti did not contribute to revenue during this reporting period.-Fineline Info & Tech